To compare the relative effectiveness of angiotensin-converting enzyme inhibitors (ACEIs)
and angiotensin receptor blockers (ARBs) in reducing cardiovascular mortality in chronic …

Long-term benefit of using a renin–angiotensin–aldosterone system blocker such as an
angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) …

Background and objectives: Cardiovascular (CV) disease causes significant morbidity and
mortality among the hemodialysis (HD) population. This meta-analysis was performed to …

BACKGROUND: Persons with end-stage renal disease (ESRD) on hemodialysis carry an
exceptionally high burden of cardiovascular disease. Angiotensin-converting enzyme …

BACKGROUND: Cardiovascular disease is the leading cause of mortality in patients with
kidney failure treated with hemodialysis (HD). Although angiotensin receptor blockers …

Objectives: The study objective was to assess the association between angiotensin-
converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) use and mortality in …

Patients were stratified into 1 of 3 mutually exclusive treatment groups (ACEI/ARB, CCB, or
statin) and were prospectively observed for up to 5 years, or March 31, 2010. The primary …

Background The role of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin
receptor blockers (ARBs) reducing risk of cardiovascular events (CVEs) and preserving …

Purpose There has been much controversy over the use of angiotensin‐converting enzyme
inhibitors/angiotensin receptor blockers (ACEIs/ARBs) on patients with renal dysfunction …

Background Major adverse cardiovascular events (MACE) cause the leading cause of
morbidity and mortality in patients with end-stage renal disease (ESRD) on maintenance …